Multidimensional comparative evaluation of first-line therapies for extensive-stage small cell lung cancer: a systematic review and network meta-analysis of clinical efficacy and safety profiles
Abstract Background The first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) has evolved from chemotherapy alone to chemoimmunotherapy. However, the improvements in overall survival (OS) and progression-free survival (PFS) have been modest. Therefore, this study employs a compre...
Saved in:
| Main Authors: | Ziyao Jiang, Fangrui Zhao, Butuo Li, Junyi He, Huiwen Yang, Yuhan Ji, Bing Zou, Jinming Yu, Linlin Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14750-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association Between Antibiotic and Outcomes of Chemoimmunotherapy for Extensive‐Stage Small Cell Lung Cancer: A Multicenter Retrospective Study of 132 Patients
by: Fang Deng, et al.
Published: (2025-01-01) -
Consolidative thoracic radiotherapy improves the prognosis of extensive stage small-cell lung cancer patients in the chemoimmunotherapy era: a multicenter retrospective analysis
by: Nan Yao, et al.
Published: (2025-12-01) -
Efficacy and safety of first-line chemoimmunotherapy in young patients with extensive-stage small cell lung cancer: a multicenter retrospective study
by: Lijuan Zhao, et al.
Published: (2025-07-01) -
The combination of chemotherapy and immune checkpoint inhibitors in recurrent extensive-stage small cell lung cancer: a case report
by: Chunxiu Hu, et al.
Published: (2025-07-01) -
Comparative Efficacy of PD‐1 Inhibitor‐Based Neoadjuvant Chemoimmunotherapy Regimens for Resectable Stage II–IIIa NSCLC: A Real‐World Retrospective Study
by: Bo Yan, et al.
Published: (2025-07-01)